Global transgenic upregulation of KCC2 confers enhanced diazepam efficacy in treating sustained seizures.

Reduced anticonvulsant efficacy of benzodiazepines is a problem in the treatment of status epilepticus, with up to 50% of patients failing to respond to their first dose. KCC2 is a neuronal K -Cl co-transporter that helps set and maintain intracellular Cl concentrations. KCC2 functional downregulation is a potential contributor to benzodiazepine resistance.